References

problendo

Проблемы Эндокринологии

Problems of Endocrinology

0375-96602308-1430

Endocrinology Research Centre

10.14341/probl201157135-45

problendo-4580

Research Article

Статьи

Articles

Остеопороз - от редкого симптома эндокринных болезней до безмолвной эпидемии XX-XXI века

Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX-XXI centuries

Dedov

I I

Mel'nichenko

G A

Belaia

Zh E

jannabelaya@gmail.com

Rozhinskaia

L Ia

2011

15022011

571

ТОМ 57, №1 (2011)

3545

2011

Dedov I.I., Mel'nichenko G.A., Belaia Z.E., Rozhinskaia L.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.probl-endojournals.ru/jour/article/view/4580

Обсуждается история развития знаний о первичном и вторичном остеопорозе, эпидемиология, этиология и особенности диагностики разных форм остеопороза. Отдельное внимание уделяется вопросам лечения заболевания, с точки зрения доказательной медицины, выбору оптимального препарата при первичном остеопорозе на основании данных многоцентровых рандомизированных плацебо-контролируемых исследований, а также исследованиям эффективности различных препаратов при вторичных формах остеопороза и смешанном характере заболевания, проводимых в том числе на базе ФГУ ЭНЦ. Уделяется внимание особенностям анализа результатов исследований и сравнительным характеристикам эффективности препаратов.

This article describes the history of knowledge management with special reference to primary and secondary osteoporosis, its epidemiology and diagnostics of different forms of this disease. The discussion is focused on therapeutic modalities for the treatment of osteoporosis based on the principles of evidence-based medicine. Special attention is given to the choice of optimal medicinal preparations for the management of primary osteoporosis taking into account results of multicenter randomized placebo-controlled clinical studies and the results of evaluation of the efficacy of various pharmaceutical for the treatment of secondary osteoporosis and its mixed forms. Some of these studies are carried out based at the Endocrinological Research Centre. Peculiarities of analysis of their results are discussed along with comparative characteristics of selected pharmaceuticals.

первичный остеопорозвторичный остеопорозабсолютный риск переломовотносительный риск переломовбисфосфонаты

primary and secondary osteoporosisabsolute risk of fracturerelative risk of fracturebiophosphonates

References1

Schapira D., Schapira C. Osteoporosis: the evolution of a scientific term. Osteoporos Int 1992;2:4:164-167.

Recklinghausen F.D. Die fibrose oder deformierende ositis, die osteomalazie und die osteoplastische carzinose in ihren gegenseitigen beziehungen. Festchrift Rudolf Virchow. George Reimer. Berlin 1891;1.

Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137-195.

Kanis J.A., Johnell O., Oden A. et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000;11:8:669-674.

Rizzoli R. Atlas of postmenopausal osteoporosis. 3-rd Ed. Curr Med Group 2010;33-60.

O'Neill T.W., Felsenberg D., Varlow J. et al. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:7:1010-1018.

Cooper C., Atkinson E.J., Jacobsen S.J. et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:9:1001-1005.

Bliuc D., Nguyen N.D., Milch V.E. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:5:513-521.

Cooper C. The crippling consequences of fractures and their consequences impact on quality of life. Am J Med 1997;103:2A:12S-17S.

Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:12:1726-1733.

Cakir B., Odabasi E., Turan M. et al. Secondary osteoporosis in women. Arch Gynecol Obstet 2002;266:4:214-217.

Дедов И.И., Рожинская Л.Я. Мокрышева Н.Г., Васильева Т.О. Этиология, патогенез, клиническая картина, диагностика и лечение первичного гиперпаратиреоза. Остеопороз и остеопатии 2010;1:13-18.

Рожинская Л.Я. Современные представления об этиологии, клинической картине, диагностике и лечении первичного гиперпаратиреоза. Лечащий врач 2009;3:15-20.

Рожинская Л.Я. Остеопенический синдром при заболеваниях эндокринной системы и постменопаузальный остеопороз (патогенетические аспекты, диагностика и лечение): Автореф. дис. … д-ра мед. наук. М 2001.

Сипина Л.В. Оценка минаральной плотности костной ткани и показателей костного метаболизма у женщин с диффузным токсическим зобом: Автореф. дис. … канд. мед. наук. М 2003.

Ben-Shlomo A., Hagag P., Evans S., Weiss M. Early postmenopausal bone loss in hyperthyroidism. Maturitas 2001;39:1:19-27.

Harvey C.B., O'Shea P.J., Scott A.J. et al. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Genet Metab 2002;75:1:17-30.

Jódar E., Muñoz-Torres M., Escobar-Jiménez F. et al. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol (Oxford) 1997;47:3:279-285.

Vestergaard P., Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 2003;13:6:585-593.

Cummings S.R., Nevitt M.C., Browner W.S. et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:12:767-773.

Bauer D.C., Nevitt M.C., Ettinger B., Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997;82:9:2931-2936.

Kim D.J., Khang Y.H., Koh J.M. et al. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol (Oxford) 2006;64:1:86-90.

Morris M.S. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 2007;40:4:1128-1134.

Jamal S.A., Leiter R.E., Bayoumi A.M. et al. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005;16:5:534-540.

Lee W.Y., Oh K.W., Rhee E.J. et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 2006;37:4:511-516.

Novack D.V. TSH, the bone suppressing hormone. Cell 2003;115:2:129-130.

Sun L., Davies T.F., Blair H.C. et al. TSH and bone loss. Ann N Y Acad Sci 2006;1068:309-318.

Tsai J.A., Janson A., Bucht E. et al. Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-like cells. Calcif Tissue Int 2004;74:5:486-491.

Deure V.W.M., Uitterlinden A.G., Pols H.A.P. et al. The TSH receptor ASP727GLU polymorphism is associated with higher bone mineral density and bone mineral content. Thyroid 2005;15:20-21.

Abe E., Marians R.C., Yu W. et al. TSH is a negative regulator of skeletal remodeling. Cell 2003;115:2:151-162.

Riggs B.L., Khosla S., Melton L.J. 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:3:279-302.

Белая Ж.Е., Мельниченко Г.А., Рожинская Л.Я. и др. Минеральная плотность костной ткани и показатели костного метаболизма у женщин в менопаузе с субклиническим тиреотоксикозом различного генеза. Остеопороз и остеопатии 2006;1:13-17.

Morimura T., Tsunekawa K., Kasahara T. et al. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005;146:4:2077-2084.

Bianco A.C., Salvatore D., Gereben B. et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:1:38-89.

Baldini M., Gallazzi M., Orsatti A. et al. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Int Med 2002;251:5:407-414.

Quan M.L., Pasieka J.L., Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79:1:62-69.

Schneider R., Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabet 2003;111:8:455-470.

Zelmanovitz F., Genro S., Gross J.L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998;83:11:3881-3885.

Janghorbani M., Van Dam R.M., Willett W.C., Hu F.B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:5:495-505.

Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis Osteoporos. Int 2007;18:4:427-444.

Vestergaard P., Rejnmark L., Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:1:45-55.

Рожинская Л.Я. Нарушения минерального обмена, костного метаболизма и их коррекция при болезни Иценко-Кушинга: Автореф. дис. ... канд. мед. наук. М 1991.

Belaya Z., Sosunova N., Rozhinskaya L. et al. Fractures and bone remodeling in patients with endogenous hypercorticism. Abstract book of European Neuroendocrine Association 22-25 September 2010. Liege (Belgium) 2010;117.

Лесняк О.М., Беневоленская Л.И. Российские клинические рекомендации: Остеопороз. Диагностика, профилактика и лечение. М 2009;225-251.

Füto L., Toke J., Patócs A. et al. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporos Int 2008;19:7:941-949.

Barahona M.J., Sucunza N., Resmini E. et al. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 2009;24:11:1841-1846.

Pivonello R., De Martino M.C., De Leo M. et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metab 2007;51:8:1381-1391.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series. WHO 1994;843:1-129.

Kanis J.A., Burlet N., Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:4:399-428.

Kanis J.A., Johansson H., Oden A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:6:893-899.

Белая Ж.Е., Рожинская Л.Я., Сосунова Н.В. Альфакальцидол (Альфа Д3-Тева) - препарат с многокомпонентным действием на снижение риска переломов. Остеопороз и остеопатии 2008;1:22-28.

Белая Ж.Е., Рожинская Л.Я. Падения - важная социальная проблема пожилых людей. Основные механизмы развития и пути предупреждения. Рус мед журн 2009;17:1614-1619.

Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:5:459-468.

Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:5:2816-2822.

Recker R.R., Marin F., Ish-Shalom S. et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:8:1358-1368.

Blake G.M., Compston J.E., Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res 2009;24:8:1354-1357.

Li C., Paris O., Siegel S. et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 2010;25:5:968-975.

Белая Ж.Е., Рожинская Л.Я., Беляева А.В., Мельниченко Г.А. Новые возможности лечения постменопаузального остеопороза: стронция ранелат (бивалос). Пробл эндокринол 2006;52:5:47-55.

Белая Ж.Е., Рожинская Л.Я. Возможности применения паратиреоидного гормона для лечения остеопороза. Остеопороз и остеопатии 2004;3:26-33.

Белая Ж.Е., Рожинская Л.Я. Сосунова Н.В. Роль факторов риска в диагностике остеопороза и принятии решения о назначении терапии. Эффективность бисфосфонатов в лечении остеопороза. Рус мед журн 2009;17:706-711.

Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А. Ибандронат (Бонвива) - новое направление в лечении бисфосфонатами. Лучшая приверженность к лечению - лучший результат. Остеопороз и остеопатии 2006;3:23-29.

Дедов И.И., Рожинская Л.Я., Белая Ж.Е. Роль и место бисфосфонатов в профилактике и лечении остеопороза 10-летний опыт применения алендроната. Остеопороз и остеопатии 2005;1:20-30.

Lyles K.W., Colón-Emeric C.S., Magaziner J.S. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:18:1799-1809.

McClung M., Miller P., Recknor C. et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009;114:5:999-1007.

Barratt A., Wyer P.C., Hatala R. et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:4:353-358.

Chesnut C.H. III, Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:8:1241-1249.

Eisman J.A., Civitelli R., Adami S. et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:3:488-497.

Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:5:654-661.

Wilkes M.M., Navickis R.J., Chan W.W., Lewiecki E.M. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 2010;21:4:679-688.

O'Donnell S., Moher D., Thomas K. et al. Strontium ranelate for preventing and treating osteoporosis. The Cochrane Library 2008; Issue 4:CD005326. DOI: 10.1002/14651858.CD005326.pub3.

O'Donnell S., Moher D., Thomas K. et al. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 2008;26:6:531-542.

Ringe J.D., Dorst A., Faber H. et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:10:801-807.

Fahrleitner-Pammer A., Piswanger-Soelkner J.C., Pieber T.R. et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009;24:7:1335-1344.

Белая Ж.Е., Рожинская Л.Я., Колесникова Г.С. и др. Опыт применения профилактической дозы алендроната (фосамакс 35 мг) для лечения остеопороза у женщин в постменопаузе с субклиническим тиреотоксикозом. Остеопороз и остеопатии 2007;1:12-19.

Белая Ж.Е., Рожинская Л.Я., Ильин А.В. и др. Эффективность профилактики остеопении препаратами кальция и витамина D (Кальций D3 Никомед форте) у женщин в постменопаузе с субклиническим тиреотоксикозом. Остеопороз и остеопатии 2007;2:13-18.

Sosunova N.V., Belaya Z.E., Dzeranova L.K. et al. The comparative response of biochemical parameters concerning treatment with zoledronic acid 5mg a year in patients with primary hyperparathyroidism and postmenopausal osteoporosis. Osteoporos Int 2010;21:Suppl 1:158-159.

Zaki M.E., Hussien F.H., Banna R.A. Osteoporosis among ancient Egyptians. Int J Osteoarvhaeol 2009;19:78-89.

Cooper A., Drake J., Brankin E. PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:8:896-905.

Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:9041:1535-1541.

Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:24:2077-2082.

Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:18:1809-1822.

The authors declare that there are no conflicts of interest present.